Drug Kinetics – Multimedia

With unparalleled speed, sensitivity and spatial resolution, Shimadzu’s iMScope QT imaging mass microscope clears the way to next-generation mass spectrometry imaging in areas such as biomarker tracking, pharmacokinetics, and ADME studies.

Designing and performing assays that accurately measure small molecule binding kinetics is an important part of the drug discovery process. It allows researchers to predict the efficacy of potential novel therapeutics and make quick decisions about weak binders.

Conventional bioassays often require labeled detection reagents to provide a measurable readout. However, modifications to molecular structure and/or function can skew results, and non-specific binding of the labels themselves can lead to an unwanted background signal.

Conducting in vitro ADME drug-drug interaction (DDI) studies early on in the drug development process is more than simply a box checking exercise to satisfy regulatory requirements. The information provided by these studies provides a deeper understanding of the molecule to the drug developer helping to inform go or no-go decisions early on.

Hear expert Dr. Brian Ogilvie discuss the differences between current in vitro drug-drug interaction guidance from the relevant US FDA, EMA and PMDA guidance documents, and how to plan drug development strategies to meet the ICH M12 guideline.

This presentation was one of the keynote presentations from XenoTech's XenoTalks™ Seminar Series on the importance of ADME and Drug-Drug Interactions in drug development.

This informative ADME 101 discusses In Vitro to In Vivo Extrapolation (IVIVE) and how a model-based approach following routine perpetrator potential studies (i.e. CYP inhibition, CYP induction, and transporter inhibition) assessing clinical potential may eliminate the need of conducting clinical studies.

Speaking at Advances in Drug Discovery & Development online symposium 2021, Rolf Kern from SCIEX, presented his talk on the new Echo MS system.

This ADME 101 video discusses how compounds can become trapped by lysosomes, which can lead to high organ-to-blood ratios and mistaken for active drug transport, how concomitant administration of lysosomotropics could lead to elevated drug exposure levels, and how accumulation of lipophilic amines can lead to drug-induced phospholipidosis due to decreased phospholipid catabolism.

This ADME 101 video provides an overview of different types of subcellular fractions, such as microsomes, S9, cytosol, lysosomes and homogenate, and their unique benefits for use in various types of in vitro ADMET/DMPK & Drug-Drug Interaction studies.